Back to discover
§ The cross-read
BMY vs MRNA
BMY has a published report; MRNA is awaiting first coverage, so the editorial contrast below leans on the live data row alone.
Fair-value ladder
Fair-value ladder unavailable — one or both tickers have no published mid fair value.
Aligned scorecards
Aligned scorecards unavailable — at least one ticker has no published 9-category scorecard yet.
| BMYBristol-Myers Squibb Company | MRNAModerna Inc. | |
|---|---|---|
| Trend | - | - |
| Price | - | - |
| Fair value | - | - |
| FV range | - | - |
| Upside | - | - |
| Rating | Conserver | Conserver |
| Confidence | - | - |
| Moat | - | - |
| Archetype | - | - |
| Sector | Health Care | Health Care |
| Analyzed | - | - |
9-category scorecards
BMY
Bristol-Myers Squibb Company
Valuation
5.0/10
0.11x
Management
7.3/10
0.11x
Balance Sheet
3.5/10
0.11x
Profitability
7.5/10
0.11x
Revenue Growth
4.5/10
0.11x
Risk Assessment
5.0/10
0.11x
Competitive Moat
6.5/10
0.11x
Earnings Quality
8.0/10
0.11x
Capital Efficiency
7.5/10
0.11x
Weighted Overall
6.1/10
MRNA
No published scorecard yet.